Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4863716 | 0.79 | METAP1 (0.33) | METAP1ALOX15BLMPMP22KMT2A | |
| SCHEMBL4875397 | 0.76 | ALOX15 (0.37) | ALOX15BLMPMP22KMT2A | |
| SCHEMBL4874676 | 0.74 | ALOX15 (0.35) | ALOX15BLMPMP22KMT2A | |
| SCHEMBL4866054 | 0.73 | ALOX15 (0.30) | ALOX15BLMPMP22KMT2A | |
| SCHEMBL3514739 | 0.71 | ALOX15 (0.37) | ALOX15BLMPMP22KMT2A | |
| SCHEMBL4869337 | 0.70 | BLM (0.42) | ALOX15BLMPMP22KMT2A | |
| SCHEMBL885302 | 0.67 | HPGD (0.53) | METAP1KMT2AHPGDEPHX1 | |
| SCHEMBL931218 | 0.67 | HPGD (0.53) | METAP1KMT2AHPGDEPHX1 | |
| SCHEMBL5483408 | 0.66 | FOLH1 (0.39) | ALOX15BLMPMP22KMT2ASLC1A3 | |
| SCHEMBL9100 | 0.66 | SIGMAR1 (0.50) | METAP1KMT2AHPGDEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | disclosed |
| EP-1599487-B1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2007-07-11 | — | — | EP | disclosed |
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2006-03-09 | — | — | US | disclosed |
| EP-1599487-A1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | Givaudan SA (CH) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004043971-A1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GLUL, GRIA1, GRM1 | METAP1 585/4885ALOX15 852/4885BLM 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.